Curcumin and cancer: barriers to obtaining a health claim

被引:186
作者
Devassy, Jessay G. [1 ]
Nwachukwu, Ifeanyi D. [1 ]
Jones, Peter J. H. [1 ,2 ]
机构
[1] Univ Manitoba, Dept Human Nutr Sci, Winnipeg, MB R3T 2N2, Canada
[2] Univ Manitoba, Richardson Ctr Funct Foods & Nutraceut, Winnipeg, MB R3T 2N2, Canada
关键词
cancer; curcumin; health claim; turmeric; MULTIPLE ANTIOXIDANT VITAMINS; AQUEOUS TURMERIC EXTRACT; COLORECTAL-CANCER; CLINICAL-TRIAL; BREAST-CANCER; DNA-DAMAGE; CHEMOPREVENTIVE EFFICACY; ANTIMICROBIAL ACTIVITY; COMPARATIVE ABSORPTION; ORAL BIOAVAILABILITY;
D O I
10.1093/nutrit/nuu064
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Curcumin is a highly pleiotropic molecule found in the rhizomes of Curcuma longa (turmeric). It is responsible for the yellow color of turmeric and has been shown to inhibit the proliferation of cancer cells and to be of use in preventing or treating a number of diseases. Curcumin has been shown to modulate multiple cell-signaling pathways simultaneously, thereby mitigating or preventing many different types of cancers, including multiple myeloma and colorectal, pancreatic, breast, prostate, lung, head, and neck cancers, in both animal models and humans. Current therapeutic approaches using a single cancer drug for a single target can be expensive, have serious side effects, or both. Consequently, new approaches to the treatment and prevention of cancer, including the integration of curcumin as a viable treatment strategy where dysregulation of many pathways is involved, are warranted. A methodical review of the evidence was performed to evaluate the effects of curcumin in support of a health claim, as established through the regulatory framework of Health Canada, for a relationship between the consumption of curcumin and the prevention and treatment of cancer.
引用
收藏
页码:155 / 165
页数:11
相关论文
共 106 条
[1]
Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model [J].
Adapala, Nagasuresh ;
Chan, Marion M. .
LABORATORY INVESTIGATION, 2008, 88 (12) :1329-1339
[2]
Aggarwal BB, 2003, ANTICANCER RES, V23, P363
[3]
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
[4]
PHARMACOLOGY OF CURCUMA-LONGA [J].
AMMON, HPT ;
WAHL, MA .
PLANTA MEDICA, 1991, 57 (01) :1-7
[5]
Curcumin and cancer: An "old-age" disease with an "age-old" solution [J].
Anand, Preetha ;
Sundaram, Chitra ;
Jhurani, Sonia ;
Kunnumakkara, Ajaikumar B. ;
Aggarwal, Bharat B. .
CANCER LETTERS, 2008, 267 (01) :133-164
[6]
Bioavailability of curcumin: Problems and promises [J].
Anand, Preetha ;
Kunnumakkara, Ajaikumar B. ;
Newman, Robert A. ;
Aggarwal, Bharat B. .
MOLECULAR PHARMACEUTICS, 2007, 4 (06) :807-818
[7]
A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95® CG (Biocurcumax™), A Novel Bioenhanced Preparation of Curcumin [J].
Antony, B. ;
Merina, B. ;
Iyer, V. S. ;
Judy, N. ;
Lennertz, K. ;
Joyal, S. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 70 (04) :445-449
[8]
Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products [J].
Appiah-Opong, Regina ;
Commandeur, Jan N. M. ;
van Vugt-Lussenburg, Barbara ;
Vermeulen, Nico P. E. .
TOXICOLOGY, 2007, 235 (1-2) :83-91
[9]
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer [J].
Bayet-Robert, Mathilde ;
Kwiatkowski, Fabrice ;
Leheurteur, Marianne ;
Gachon, Francoise ;
Planchat, Eloise ;
Abrial, Catherine ;
Mouret-Reynier, Marie-Ange ;
Durando, Xavier ;
Barthomeuf, Chantal ;
Chollet, Philippe .
CANCER BIOLOGY & THERAPY, 2010, 9 (01) :8-14
[10]
Brush M, 2012, NUTR BUS J, V17, P16